Seeking people aged 2-21 years who have been diagnosed with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive Acute Lymphoblastic Leukemia (ALL) for a study of whether using a less toxic chemotherapy in combination with a drug called imatinib can keep the cancer from returning after treatment.
Participants in this study will receive chemotherapy in combination with imatinib. What type of chemotherapy the participant will receive will be based on a bone marrow or blood test for minimal residual disease.
What we're hoping for
This study will evaluate whether using a less toxic chemotherapy in combination with a drug called imatinib can help prevent Acute Lymphoblastic Leukemia (ALL) from coming back after treatment.
ClinicalTrials.gov Identifier: NCT03007147